Protein Kinase Regulation and GTPase Signaling
Moving in bioRxiv, Cancer Research, Cell Reports, eLife, Cancer Discovery, EMBO Reports, Environmental pollution, Gastroenterology.
- Moved this week
- 0
Rebuilt
Moved this week
Nothing in this area has moved yet this week.
Latest in Protein Kinase Regulation and GTPase Signaling
Newest first · last 60 days
Targeting oncomucin-driven immune suppression enhances K-ras(G12D) inhibitor effectiveness in pancreatic cancer, reducing tumor burden and immune checkpoints.
- Open access
- 1 cites
Lineage transformation to squamous identity enables KRAS inhibitor resistance in mouse lung adenocarcinoma models, independent of KRAS/MAPK pathway reactivation.
Greatwall kinase controls cytokinesis and cell cycle in AML cells via a novel pathway independent of ENSA-PP2A-B55, revealing a unique regulatory mechanism.
- Open access
Gβ3γ3 acts as a critical positive allosteric modulator, reorienting PLCβ3 to enhance activation and PI(4,5)P2 hydrolysis at the plasma membrane.
- Open access
KRASG12R pancreatic cancer cells develop resistance to daraxonrasib via EGFR/RASWT signaling, enabling effective trametinib-based therapy and extending patient survival to 40 months.
- Open access
A novel ∼54-kDa protein, MSEP, encoded by the ARHGEF17-AS1 locus, is essential for mitotic spindle organization and localizes to spindle poles.
- Open access
Targeting RAS mutations offers promising strategies for intercepting pancreatic cancer at its precancerous stage.
PADI1 and PADI3 promote resistance to KRAS inhibitors by sustaining mitochondrial adaptation in KRAS-driven tumors.
- Open access
SLAP suppresses EPHB2-SFK signaling, preventing excessive colonic epithelial proliferation and tumor development, highlighting its role as a tumor suppressor in the colon.
- Open access
- 1 cites
A leucine-rich repeat receptor kinase called CERI is essential for systemic nitrogen-demand signalling in plants, with CERI loss impairing this process in Arabidopsis.
HRS-4642 combined with chemotherapy achieves a 63.3% objective response rate in advanced KRAS(G12D)-mutant pancreatic cancer, showing promising antitumor activity.
Disruption of TTN uORFs does not increase titin expression in human cardiomyocytes, revealing context-dependent regulation of TTN translation.
- Open access
KRASG12R mutants in pancreatic cancer develop resistance to daraxonrasib via EGFR/RASWT signaling, enabling effective trametinib-based therapy and extended patient survival.
Small-molecule inhibitors targeting RAS/RAF disrupt allosteric RAF conformation, effectively treating diverse RAS-driven cancers with a broad-spectrum approach.
- Open access
Follow this area in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1746
- Environ Res483
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ199
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- J Exp Bot115
- Curr Biol112
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4